• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Recommendation for Appropriate Use of Sodium Glucose Cotransporter 2 Inhibitors in Treatment of Heart Failure.

作者信息

Tanaka Atsushi, Kinugawa Koichiro, Kuwahara Koichiro, Ito Hiroshi, Murohara Toyoaki, Hirata Ken-Ichi, Node Koichi

机构信息

Department of Cardiovascular Medicine, Saga University.

Second Department of Internal Medicine, University of Toyama.

出版信息

Circ J. 2023 Oct 25;87(11):1707-1709. doi: 10.1253/circj.CJ-23-0605. Epub 2023 Sep 22.

DOI:10.1253/circj.CJ-23-0605
PMID:37743518
Abstract
摘要

相似文献

1
Recommendation for Appropriate Use of Sodium Glucose Cotransporter 2 Inhibitors in Treatment of Heart Failure.钠-葡萄糖协同转运蛋白2抑制剂在心力衰竭治疗中合理应用的推荐意见。
Circ J. 2023 Oct 25;87(11):1707-1709. doi: 10.1253/circj.CJ-23-0605. Epub 2023 Sep 22.
2
Sodium-glucose cotransporter 2 inhibitors in hospitalized heart failure patients: No time like now.
Eur J Heart Fail. 2023 Oct;25(10):1806-1807. doi: 10.1002/ejhf.3022. Epub 2023 Sep 10.
3
Sodium-glucose cotransporter 2 inhibitors for chronic heart failure: The ultimate solution?
Eur J Heart Fail. 2023 Aug;25(8):1361-1363. doi: 10.1002/ejhf.2942. Epub 2023 Jun 27.
4
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction.钠-葡萄糖共转运蛋白 2 抑制剂在射血分数保留的心力衰竭患者中的疗效比较。
Pharmacotherapy. 2023 Oct;43(10):1024-1031. doi: 10.1002/phar.2853. Epub 2023 Jul 23.
5
Letter regarding the article 'Little at a time: trying to understand the battery of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure'.
Eur J Heart Fail. 2023 Apr;25(4):598. doi: 10.1002/ejhf.2782. Epub 2023 Feb 6.
6
Sodium-glucose cotransporter 2 inhibitors reduce cardiovascular events in acute heart failure. A real-world analysis.
Eur J Intern Med. 2022 Oct;104:128-130. doi: 10.1016/j.ejim.2022.06.008. Epub 2022 Jun 27.
7
Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.根据基线时降糖药物的使用情况，评估卡格列净对 2 型糖尿病合并慢性心力衰竭患者 N 末端脑利钠肽前体的影响。
Cardiovasc Diabetol. 2021 Sep 3;20(1):175. doi: 10.1186/s12933-021-01369-5.
8
Mortality Outcomes With Different Sodium-glucose Cotransporter-2 Inhibitors: Are They Dissimilar?
Endocr Pract. 2022 Oct;28(10):1107-1108. doi: 10.1016/j.eprac.2022.07.001. Epub 2022 Jul 9.
9
Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.钠-葡萄糖共转运蛋白 2 抑制剂在心力衰竭预防和治疗中的临床应用：超越 2 型糖尿病。一篇叙述性综述。
Adv Ther. 2022 Feb;39(2):845-861. doi: 10.1007/s12325-021-01989-z. Epub 2021 Dec 9.
10
Letter by Koh Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".科关于文章《钠-葡萄糖协同转运蛋白2抑制剂起始治疗患者与其他降糖药物相比心力衰竭和死亡风险更低：CVD-REAL研究（钠-葡萄糖协同转运蛋白2抑制剂新使用者心血管结局的比较有效性）》的信
Circulation. 2018 Feb 27;137(9):984-985. doi: 10.1161/CIRCULATIONAHA.117.030650.

引用本文的文献

1
Comparative Effects of Empagliflozin and Dapagliflozin in Stable Chronic Heart Failure　- A Prospective Crossover Study.恩格列净与达格列净对稳定型慢性心力衰竭的比较效应——一项前瞻性交叉研究。
Circ Rep. 2025 Jun 27;7(8):639-645. doi: 10.1253/circrep.CR-25-0085. eCollection 2025 Aug 8.
2
Rationale and Protocol of the Registry for Contemporary Medical Management of Chronic Heart Failure With Mildly Reduced and Preserved Ejection Fraction　- The PARACLETE Study.射血分数轻度降低和保留的慢性心力衰竭当代医学管理登记研究的原理与方案——帕拉克莱特研究
Circ Rep. 2025 May 14;7(6):491-496. doi: 10.1253/circrep.CR-24-0138. eCollection 2025 Jun 10.
3
Clinical use and monitoring of adverse effects of sodium-glucose cotransporter-2 inhibitors in persons with type 1 diabetes mellitus.
1型糖尿病患者中钠-葡萄糖协同转运蛋白2抑制剂的临床应用及不良反应监测
J Diabetes Investig. 2025 Aug;16(8):1420-1429. doi: 10.1111/jdi.70085. Epub 2025 May 26.
4
Diabetes mellitus aggravates myocardial inflammation and oxidative stress in aortic stenosis: a mechanistic link to HFpEF features.糖尿病会加重主动脉瓣狭窄中的心肌炎症和氧化应激：与射血分数保留的心力衰竭特征的机制联系。
Cardiovasc Diabetol. 2025 May 13;24(1):203. doi: 10.1186/s12933-025-02748-y.
5
Euglycemic Ketoacidosis in a Patient without Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure.心力衰竭患者服用钠-葡萄糖共转运蛋白 2 抑制剂后出现血糖正常性酮症酸中毒。
Am J Case Rep. 2024 Jul 10;25:e943945. doi: 10.12659/AJCR.943945.